Challenges in elucidating the genetics of diabetic retinopathy

JAMA Ophthalmology

Volumn 132, Issue 1, 2014, Pages 96-107

  Kuo, Jane Z ^a,c,d   Wong, Tien Y ^b,e   Rotter, Jerome I ^a,f   Wiggs, Janey L ^g  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f HARBOR UCLA MEDICAL CENTER   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DIABETIC RETINOPATHY; ENVIRONMENTAL FACTOR; EXOME; FAMILY STUDY; GENE; GENETIC ASSOCIATION; GENETICS; HEREDITY; HERITABILITY; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SAMPLE SIZE; SCORING SYSTEM;

DIABETIC RETINOPATHY; GENETIC LINKAGE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MOLECULAR BIOLOGY; QUANTITATIVE TRAIT, HERITABLE; TRANSCRIPTOME; TWIN STUDIES AS TOPIC;

EID: 84892714171     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.5024     Document Type: Article

References (122)

1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105(10):1801-1815. (Pubitemid 28509717)
2. Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556-564.
3. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010;304(6):649-656.
4. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol. 2006;141(3):446-455.
5. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389. (Pubitemid 40530070)
6. Solouki AM, Verhoeven VJ, van Duijn CM, et al. A genome-wide association study identifies a susceptibility locus for refractive errors and myopia at 15q14. Nat Genet. 2010;42(10):897-901.
7. Hysi PG, Young TL, Mackey DA, et al. A genome-wide association study formyopia and refractive error identifies a susceptibility locus at 15q25. Nat Genet. 2010;42(10):902-905.
8. Burdon KP, Macgregor S, Hewitt AW, et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nat Genet. 2011;43(6):574-578.
9. Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet. 2010;42(10):906-909.
10. Leslie RD, Pyke DA. Diabetic retinopathy in identical twins. Diabetes. 1982;31(1):19-21. (Pubitemid 12254626)
11. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes. 1997;46(11):1829-1839.
12. Hietala K, Forsblom C, Summanen P, Groop PH; Finn Diane Study Group. Heritability of proliferative diabetic retinopathy. Diabetes. 2008;57(8): 2176-2180.
13. Looker HC, Nelson RG, Chew E, et al. Genome-wide linkage analyses to identify loci for diabetic retinopathy. Diabetes. 2007;56(4): 1160-1166. (Pubitemid 46525074)
14. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian type 2 diabetic patients. Diab Med. 2002;19(11):910-916. (Pubitemid 35356916)
15. Zhang X, Gao Y, Zhou Z, Wang J, Zhou Q, Li Q. Familial clustering of diabetic retinopathy in Chongqing, China, type 2 diabetic patients. Eur J Ophthalmol. 2010;20(5):911-918.
16. Hallman DM, Huber JC Jr, Gonzalez VH, Klein BE, Klein R, Hanis CL. Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care. 2005;28(5):1163-1168. (Pubitemid 40616629)
17. Arar NH, Freedman BI, Adler SG, et al; Family Investigation of Nephropathy and Diabetes Research Group. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest Ophthalmol Vis Sci. 2008;49(9):3839-3845.
18. Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy. Int Ophthalmol Clin. 2009;49(2):35-52.
19. Ng DP. Human genetics of diabetic retinopathy: current perspectives. J Ophthalmol. 2010;2010:172593.
20. Abhary S, Hewitt AW, Burdon KP, Craig JE. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes. 2009;58(9):2137-2147.
21. Zhao T, Zhao J. Association between the-634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: ameta-analysis. Diabetes Res Clin Pract. 2010;90(1):45-53.
22. Sobrin L, Green T, Sim X, et al; Family Investigation of Nephropathy and Diabetes-Eye Research Group;Wellcome Trust Case Control Consortium 2. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011;52(10):7593-7602.
23. Hallman DM, Boerwinkle E, Gonzalez VH, Klein BE, Klein R, Hanis CL. A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas. Diabetes. 2007;56(4):1167-1173. (Pubitemid 46525075)
24. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC; Pima Diabetes Genes Group. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Diabetes. 1998;47(5):821-830. (Pubitemid 28201814)
25. Fu YP, Hallman DM, Gonzalez VH, et al. Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr County, Texas. J Ophthalmol. 2010;2010:861291.
26. Huang YC, Lin JM, Lin HJ, et al. Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011;118(4):642-648.
27. Grassi MA, Tikhomirov A, Ramalingam S, Below JE, Cox NJ, Nicolae DL. Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet. 2011;20(12):2472-2481.
28. Sheu WH, Kuo JZ, Lee IT, et al. Genome-wide association study in a Chinese population with diabetic retinopathy. Hum Mol Genet. 2013;22(15):3165-3173.
29. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(9614): 736-743. (Pubitemid 351288874)
30. Klein R, Klein BE, Moss SE, Wong TY. The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2006;104:98-107.
31. Buabbud JC, Al-latayfeh MM, Sun JK. Optical coherence tomography imaging for diabetic retinopathy and macular edema. Curr Diab Rep. 2010;10(4):264-269.
32. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. Am J Hum Genet. 2012;90(1):7-24.
33. Morris AP, Voight BF, Teslovich TM, et al; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44(9):981-990.
34. Kuo JZ, Sheu WH, Assimes TL, et al. Trans-ethnic fine mapping identifies a novel independent locus at the 3' end of CDKAL1 and novel variants of several susceptibility loci for type 2 diabetes in a Han Chinese population [published online ahead of print September 8, 2013]. Diabetologia. doi:10.1007/s00125-013- 3047-1.
35. Palmer ND, Goodarzi MO, Langefeld CD, et al. Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study. Diabetes. 2008;57(4):1093-1100.
36. Ng MC, Saxena R, Li J, et al. Transferability and fine mapping of type 2 diabetes loci in African Americans: the Candidate Gene Association Resource Plus Study. Diabetes. 2013;62(3):965-976.
37. Liu CT, Ng MC, Rybin D, et al. Transferability and fine-mapping of glucose and insulin quantitative trait loci across populations: CARe, the Candidate Gene Association Resource. Diabetologia. 2012;55(11):2970-2984.
38. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010;1212:59-77.
39. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14): 977-986.
40. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
41. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy, II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520-526. (Pubitemid 14127838)
42. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, III: prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527-532. (Pubitemid 14127839)
43. Chew EY, Ambrosius WT, Davis MD, et al; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-244.
44. Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004;122(11):1631-1640. (Pubitemid 39473407)
45. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
46. Lim LS, Wong TY. Lipids and diabetic retinopathy. Expert Opin Biol Ther. 2012;12(1):93-105.
47. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861.
48. Sun JK, Keenan HA, Cavallerano JD, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. Diabetes Care. 2011;34(4):968-974.
49. Hirsch IB, Brownlee M. Beyond hemoglobin A1c: need for additional markers of risk for diabetic microvascular complications. JAMA. 2010;303(22):2291-2292.
50. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk ofmicrovascular complications in the diabetes control and complications trial-revisited. Diabetes. 2008;57(4):995-1001.
51. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-1239.
52. Jensen RA, Sim X, Li X, et al; Blue Mountains Eye Study GWAS Team; CKDGen Consortium. Genome-wide association study of retinopathy in individuals without diabetes. PLoS One. 2013;8(2):e54232.
53. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? a U.S. population study. Diabetes Care. 1998;21(8):1230-1235. (Pubitemid 28365675)
54. Klein R, Sharrett AR, Klein BE, et al; ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology. 2002;109(7):1225-1234. (Pubitemid 34700911)
55. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy inMexican Americans and non-Hispanic whites. Diabetes. 1988;37(7):878-884. (Pubitemid 19043715)
56. Haffner SM, Hazuda HP, Stern MP, Patterson JK, Van Heuven WA, Fong D. Effects of socioeconomic status on hyperglycemia and retinopathy levels in Mexican Americans with NIDDM. Diabetes Care. 1989;12(2):128-134. (Pubitemid 19064406)
57. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316(10):599-606. (Pubitemid 17024483)
58. Obrosova IG, Kador PF. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr Pharm Biotechnol. 2011;12(3):373-385.
59. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353(8):839-841. (Pubitemid 41215495)
60. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487. (Pubitemid 24356306)
61. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136.
62. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96(9):1157-1158.
63. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51(5):1635-1639. (Pubitemid 34826636)
64. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant. 2007;22(3):827-832. (Pubitemid 46351692)
65. Kangas-Kontio T, Vavuli S, Kakko SJ, et al. Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br J Ophthalmol. 2009;93(10): 1401-1406.
66. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Klin Exp Ophthalmol. 2009;247(1):21-26.
67. Petrovic MG, Korosec P, Kosnik M, et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 2008;14:1382-1387.
68. Suganthalakshmi B, Anand R, Kim R, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006;12:336-341.
69. Szaflik JP, Wysocki T, Kowalski M, et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Klin Exp Ophthalmol. 2008;246(1):39-43. (Pubitemid 350162682)
70. Uthra S, Raman R, Mukesh BN, et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet. 2008;29(1):11-15. (Pubitemid 351431242)
71. Yang Y, Andresen BT, Yang K, et al. Association of vascular endothelial growth factor-634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp Biol Med (Maywood). 2010;235(10):1204-1211.
72. Churchill AJ, Carter JG, Ramsden C, et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49(8):3611-3616.
73. Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications. 2003;17(1):1-6. (Pubitemid 36042784)
74. Chun MY, Hwang HS, Cho HY, et al. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab. 2010;95(7):3547-3551.
75. Yang X, Deng Y, Gu H, et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis. 2011;17:3088-3096.
76. Abhary S, Burdon KP, Gupta A, et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50(12):5552-5558.
77. Nakanishi K, Watanabe C. Single nucleotide polymorphisms of vascular endothelial growth factor gene intron 2 are markers for early progression of diabetic retinopathy in Japanesewith type 1 diabetes. Clin Chim Acta. 2009;402(1-2):171-175.
78. Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R. Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2006;114(6):275-294. (Pubitemid 44166174)
79. Li H, Louey JW, Choy KW, et al. EDN1 Lys198Asn is associated with diabetic retinopathy in type 2 diabetes. Mol Vis. 2008;14:1698-1704.
80. Liang S, Pan M, Hu N, et al. Association of angiotensin-converting enzyme gene 2350 G/A polymorphism with diabetic retinopathy in Chinese Han population. Mol Biol Rep. 2013;40(1):463-468.
81. Santos A, Salguero ML, Gurrola C, Muñoz F, Roig-Melo E, Panduro A. The epsilon4 allele of apolipoprotein E gene is a potential risk factor for the severity of macular edema in type 2 diabetic Mexican patients. Ophthalmic Genet. 2002;23(1):13-19. (Pubitemid 34264330)
82. Liew G, Shankar A, Wang JJ, et al. Apolipoprotein E gene polymorphisms are not associatedwith diabetic retinopathy: the atherosclerosis risk in communities study. Am J Ophthalmol. 2006;142(1):105-111. (Pubitemid 43946802)
83. Bazzaz JT, Amoli MM, Pravica V, et al. eNOS gene polymorphism association with retinopathy in type 1 diabetes. Ophthalmic Genet. 2010;31(3):103-107.
84. Szaflik JP, Majsterek I, Kowalski M, et al. Association between sorbitol dehydrogenase gene polymorphisms and type 2 diabetic retinopathy. Exp Eye Res. 2008;86(4):647-652.
85. Balasubbu S, Sundaresan P, Rajendran A, et al. Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Med Genet. 2010;11:158.
86. Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indianswith type 2 diabetes. Diabetes Care. 1997;20(8):1304-1309. (Pubitemid 27318377)
87. Lindholm E, Bakhtadze E, Sjögren M, et al. The-374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients. Diabetologia. 2006;49(11):2745-2755.
88. Ramprasad S, Radha V, Mathias RA, Majumder PP, Rao MR, Rema M. Rage gene promoter polymorphisms and diabetic retinopathy in a clinic-based population from South India. Eye (Lond). 2007;21(3):395-401. (Pubitemid 46358804)
89. Hudson BI, Stickland MH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes. 2001;50(6):1505-1511. (Pubitemid 32500186)
90. Demiryurek AT, Erbagci I, Oztuzcu S, et al. Lack of association between the Thr431Asn and Arg83Lys polymorphisms of the ROCK2 gene and diabetic retinopathy. Curr Eye Res. 2010;35(12):1128-1134.
91. Hu C, Zhang R, Yu W, et al. CPVL/CHN2 genetic variant is associated with diabetic retinopathy in Chinese type 2 diabetic patients. Diabetes. 2011;60(11):3085-3089.
92. Tian C, Fang S, Du X, Jia C. Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia. 2011;54(4):803-811.
93. Abhary S, Burdon KP, Gupta A, Petrovsky N, Craig JE. Diabetic retinopathy is not associated with carbonic anhydrase gene polymorphisms. Mol Vis. 2009;15:1179-1184.
94. Gragnoli C. Proteasome modulator 9 gene is linked to diabetic and non-diabetic retinopathy in T2D. Ophthalmic Genet. 2011;32(4):228-230.
95. Roy MS, Hallman DM, Fu YP, Machado M, Hanis CL. Assessment of 193 candidate genes for retinopathy in African Americans with type 1 diabetes. Arch Ophthalmol. 2009;127(5):605-612.
96. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599-603. (Pubitemid 32531408)
97. Grassi MA, Tikhomirov A, Ramalingam S, et al. Replication analysis for severe diabetic retinopathy. Invest Ophthalmol Vis Sci. 2012;53(4):2377-2381.
98. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466(7307):707- 713.
99. Dupuis J, Langenberg C, Prokopenko I, et al; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of Procardis Consortium; MAGIC investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42(2):105-116.
100. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363(24):2339-2350.
101. Kuo JZ, Guo X, Klein R, et al. Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics. Ophthalmology. 2012;119(5):1041-1046.
102. Klein BE, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy:Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009;127(9):1175-1182.
103. Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32(9):1704-1709.
104. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci. 2001;42(7):1586-1591. (Pubitemid 32520752)
105. Limb GA, Soomro H, Janikoun S, Hollifield RD, Shilling J. Evidence for control of tumour necrosis factor-alpha (TNF-alpha) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin Exp Immunol. 1999;115(3):409-414. (Pubitemid 29130353)
106. Meleth AD, Agrón E, Chan CC, et al. Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46(11):4295-4301. (Pubitemid 44264635)
107. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res. 2008;7(6):2516-2525.
108. Merchant ML, Klein JB. Proteomics and diabetic retinopathy. Clin Lab Med. 2009;29(1):139-149.
109. Li X, Luo X, Lu X, Duan J, Xu G. Metabolomics study of diabetic retinopathy using gas chromatography-mass spectrometry: a comparison of stages and subtypes diagnosed by Western and Chinese medicine. Mol Biosyst. 2011;7(7): 2228-2237.
110. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009;15(2):431-440.
111. Emond MJ, Louie T, Emerson J, et al; National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project; Lung GO. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet. 2012;44(8): 886-889.
112. Boileau C, Guo DC, Hanna N, et al; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. Nat Genet. 2012;44(8):916-921.
113. Albrechtsen A, Grarup N, Li Y, et al; D.E.S.I.R. Study Group; DIAGRAM Consortium. Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia. 2013;56(2):298-310.
114. Fu W, O'Connor TD, Jun G, et al; NHLBI Exome Sequencing Project. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature. 2013;493(7431):216-220.
115. published correction appears in Nature. 2013;495(7440):270
116. Wong LP, Ong RT, Poh WT, et al. Deep whole-genome sequencing of 100 southeast Asian Malays. Am J Hum Genet. 2013;92(1):52-66.
117. Grove ML, Yu B, Cochran BJ, et al. Best practices and joint calling of the Human Exome Bead Chip: the CHARGE Consortium. PLoS One. 2013;8(7):e68095.
118. Huyghe JR, Jackson AU, Fogarty MP, et al. Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat Genet. 2013;45(2):197-201.
119. Saxena R, Hivert MF, Langenberg C, et al; GIANT consortium; MAGIC investigators. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet. 2010;42(2):142-148.
120. Ehret GB, Munroe PB, Rice KM, et al; International Consortium for Blood Pressure Genome-Wide Association Studies; CARDIoGRAM consortium; CKDGen Consortium; Kidney Gen Consortium; Echo Gen consortium; CHARGE-HF consortium. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367): 103-109.
121. Psaty BM, O'Donnell CJ, Gudnason V, et al; CHARGE Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospectivemeta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009;2(1):73-80.
122. Yoo YJ, Bull SB, Paterson AD, Waggott D, Sun L; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Were genome-wide linkage studies a waste of time? exploiting candidate regions within genome-wide association studies. Genet Epidemiol. 2010;34(2):107-118.